Comparison of Pre-Prandial s.c. Regular Insulin vs Prandial Oral Insulin in Adult Type-1 DM Subjects Receiving Basal s.c. Twice Daily Isophane Insulin (NPH).
- Resource Type
- Article
- Authors
- Guevara-Aguirre, Jaime; Guevara-Aguirre, Marco; Saavedra, Jeannette
- Source
- Diabetes. Jun2007 Supplement 1, Vol. 56, pA126-A127. 2p. 1 Chart.
- Subject
- *HYPOGLYCEMIC agents
*INSULIN therapy
*INTRAVENOUS therapy
*ORAL drug administration
*TREATMENT of diabetes
*PEOPLE with diabetes
*METABOLIC regulation
- Language
- ISSN
- 0012-1797
Participating subjects were 25 Type-1DM subjects (17M; 8F); Age 28.6y (9.0); Height 164.8cm (8.53); Weight 62.4kg (8.68); BMI22.9 (1.97); BMI23.8 (2.0). Duration of DM 9.7 (5.1) years. Stabilization period: All subjects received standard therapy (ST) with basal s.c. twice daily (BID) isophane insulin (BID-NPH) and 3 pre-prandial s.c. injections of regular insulin (TID-RI). Subsequent to SP subjects were allocated to 2 cohorts: Control Group (CG): 11 subjects (5M; 6F); Treated Group (TG): 14 subjects (14M; 2F). Subjects in CG continued receiving BID-NPH and TID-RI. Subjects in the TG received BID-NPH and TID prandial split doses of Oral Insulin (Generex Oral-lyn™ -OI). Comparison Phase (CP) lasted 99 days. Fructosamine (F) and Glycated Hemoglobin (HbA1c) were determined every 14 days. After SP, 25 adult Type-1 DM subjects underwent a 99-day CP. Near normalization of parameters of DM metabolic control was achieved in all subjects. Direct comparison of HbA1c concentrations during CP demonstrate a superior effect of Generex Oral-lyn™ over subcutaneously injected regular insulin. [ABSTRACT FROM AUTHOR]